Cited by 23Bioinformatics and Genomic NetworksComputational Drug Discovery MethodsGene expression and cancer classification

Multi-modal optimization to identify personalized biomarkers for disease prediction of individual patients with cancer

Open access
Liang, Jing, Li, Zong-Wei, Yue, Cai-Tong, Hu, Zhuo, Cheng, Han, Liu, Ze-Xian, Guo, Wei-Feng·2022·Briefings in Bioinformatics

Abstract

Finding personalized biomarkers for disease prediction of patients with cancer remains a massive challenge in precision medicine. Most methods focus on one subnetwork or module as a network biomarker; however, this ignores the early warning capabilities of other modules with different configurations of biomarkers (i.e. multi-modal personalized biomarkers). Identifying such modules would not only predict disease but also provide effective therapeutic drug target information for individual patients. To solve this problem, we developed a novel model (denoted multi-modal personalized dynamic network biomarkers (MMPDNB)) based on a multi-modal optimization mechanism and personalized dynamic network biomarker (PDNB) theory, which can provide multiple modules of personalized biomarkers and unveil their multi-modal properties. Using the genomics data of patients with breast or lung cancer from The Cancer Genome Atlas database, we validated the effectiveness of the MMPDNB model. The experimental results showed that compared with other advanced methods, MMPDNB can more effectively predict the critical state with the highest early warning signal score during cancer development. Furthermore, MMPDNB more significantly identified PDNBs containing driver and biomarker genes specific to cancer tissues. More importantly, we validated the biological significance of multi-modal PDNBs, which could provide effective drug targets of individual patients as well as markers for predicting early warning signals of the critical disease state. In conclusion, multi-modal optimization is an effective method to identify PDNBs and offers a new perspective for understanding tumor heterogeneity in cancer precision medicine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bib/bbac254

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nontextual data types play a crucial role in diagnosis, effective treatment planning, research, and patient care.

    “Moreover, nontextual data types play a crucial role in diagnosis, effective treatment planning, research, and patient care [9-11].”

    From Multimodal Large Language Models in Health Care: Applications, Challenges, and Future Outlook. (2024) · cites this paper as [10]

    The Introduction (page unavailable) describes using patients’ genomic data to predict early warning signals of cancer, and the Biologic significance section (page unavailable) identifies potential drug targets for early intervention. This supports a narrower point about nontextual molecular data in cancer prediction and treatment research, but not the broad claim about nontextual data types across diagnosis, effective treatment planning, research, and patient care. The paper’s “multi-modal” refers to alternative biomarker configurations, not different data types. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Kronfeld M, Dräger A, Aschoff M, et al. On the benefits of mul- timodal optimization for metabolic network modeling. German conference on bioinformatics 2009. Gesellschaft für Informatik eV, 2009.
  2. Liu Y-Y, Slotine J-J, Barabási A-L. Observability of complex sys- tems. Proc Natl Acad Sci 2013;110:2460.
  3. Freeman LC. A set of measures of centrality based on Between- ness. Sociometry 1977;40:35-41.

Cited by

Sorted by citations

Authors
Liang, J., Li, Z.-W., Yue, C.-T., Hu, Z., Cheng, H., Liu, Z.-X., & Guo, W.-F.
Affiliations
  • Zhengzhou University (CN)
  • School of Electrical Engineering, Zhengzhou University , Zhengzhou 450001, China
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center , Guangzhou 510060, China
Corresponding author
Guo, Wei-Feng
Venue
Briefings in Bioinformatics
Published
2022-07-21
Volume
23
Issue
5
ISSN
  • 1467-5463 (ISSN-L)
  • 1477-4054
OpenAlex
W4285987711
Cited by
23
References
57
Citations by year
2026: 6 · 2025: 7 · 2024: 6 · 2023: 4
FWCI
1.39
Type
journal article
Language
en
Open access
Locations
  • Briefings in Bioinformatics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (62002329, 61922072, 61876169, 62106230)
  • Key Scientific and Technological Projects of Henan Province (212102310083, 212102210510)
  • China Postdoctoral Science Foundation (2021M692915, 2021T140616, 2021M692920)
  • Henan Postdoctoral Foundation (202002021)
  • Research start-up funds for top doctors in Zhengzhou University (32211739, 202003019)
  • State Key Laboratory of Oncology in South China (HN2021-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
Keywords
personalized biomarkers, multimodal optimization, disease prediction, breast cancer, lung cancer, driver genes, therapeutic drug targets, tumor heterogeneity, precision medicine, network biomarkers
MeSH terms
Humans, Lung Neoplasms, Biomarkers, Genomics, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review